These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27041692)

  • 21. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
    Silvennoinen R; Anttila P; Säily M; Lundan T; Heiskanen J; Siitonen TM; Kakko S; Putkonen M; Ollikainen H; Terävä V; Kutila A; Launonen K; Räsänen A; Sikiö A; Suominen M; Bazia P; Kananen K; Selander T; Kuittinen T; Remes K; Jantunen E
    Bone Marrow Transplant; 2016 Mar; 51(3):372-6. PubMed ID: 26437056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
    Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
    Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
    Desikan KR; Barlogie B; Jagannath S; Vesole DH; Siegel D; Fassas A; Munshi N; Singhal S; Mehta J; Tindle S; Nelson J; Bracy D; Mattox S; Tricot G
    J Clin Oncol; 1998 Apr; 16(4):1547-53. PubMed ID: 9552064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.
    Condomines M; Quittet P; Lu ZY; Nadal L; Latry P; Lopez E; Baudard M; Requirand G; Duperray C; Schved JF; Rossi JF; Tarte K; Klein B
    J Immunol; 2006 Jun; 176(11):6631-9. PubMed ID: 16709821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma.
    Bogucka-Fedorczuk A; Czyz A; Kalicińska E; Sawicki M; Laszkowska-Lewko M; Wicherska-Pawłowska K; Rybka J; Szeremet A; Prajs I; Szymczak D; Wróbel T
    J Clin Apher; 2020 Aug; 35(4):246-254. PubMed ID: 32298020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
    Mark T; Stern J; Furst JR; Jayabalan D; Zafar F; LaRow A; Pearse RN; Harpel J; Shore T; Schuster MW; Leonard JP; Christos PJ; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):795-8. PubMed ID: 18541199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF.
    Min YJ; Kim SW; Suh C; Park J; Kim HJ; Kim JG; Kim TW; Lee JH; Kim SB; Lee KH; Lee JS; Kim WK; Kim SH
    J Korean Med Sci; 2000 Feb; 15(1):49-52. PubMed ID: 10719808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma.
    Park Y; Kim DS; Jeon MJ; Lee BH; Yu ES; Kang KW; Lee SR; Sung HJ; Nam MH; Yoon SY; Choi CW; Kang ES; Cho D; Kim K; Kim BS; Kim DW; Kim SJ
    J Clin Apher; 2019 Oct; 34(5):579-588. PubMed ID: 31283042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
    Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
    J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.
    Jang JE; Cheong JW; Kim SJ; Cho H; Suh C; Lee H; Eom HS; Yhim HY; Lee WS; Min CK; Lee JH; Park JS; Kim JS
    Leuk Lymphoma; 2016; 57(6):1389-97. PubMed ID: 26428939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone.
    Cremer FW; Kiel K; Wallmeier M; Haas R; Goldschmidt H; Moos M
    Exp Hematol; 1998 Sep; 26(10):969-75. PubMed ID: 9728932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.